Poolbeg Pharma plc announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome (CRS). Dr Kilcoyne is currently Chief Medical Officer at Cellectis SA focusing on the development of allogeneic CAR-T therapies.
He was previously Chief Medical Officer and Head of Research & Development at Celularity Inc., where he advanced oncology-focused allogeneic CAR-T and natural killer (NK) cell therapy programmes. He also served as Chief Medical Officer at Humanigen Inc., helping to build the immunology and oncology portfolios, focusing on the cytokine pathway, CAR-T therapies, immunotherapies and Antibody Drug Conjugates in haematology and solid tumours. Across his career, he has held senior leadership roles in research & development, medical affairs, commercial strategy, health economics and outcomes research at major pharmaceutical and biotechnology companies including AstraZeneca, Celgene, Sanofi, Roche, and Eli Lilly.
Dr Kilcoyne's clinical training began after graduating from Trinity College Dublin Medical School. He trained in Gynaecological Oncology at Hammersmith Hospital, London and later pursued advanced public health training at Oxford, earning a Master's in Public Health. He subsequently completed professional training in pharmaceutical medicine and earned an MBA from Warwick Business School.
